SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Felson DT. Identifying different osteoarthritis phenotypes through epidemiology. Osteoarthritis Cartilage 2010; 18: 6014.
  • 2
    Van den Berg WB. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 2011; 19: 33841.
  • 3
    Van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010; 18: 60512.
  • 4
    Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 2007; 19: 44450.
  • 5
    Mobasheri A, Henrotin Y. Biomarkers of osteoarthritis: a review of recent research progress on soluble biochemical markers, published patents and areas for future development. Recent Pat Biomark 2011; 1: 2543.
  • 6
    Deberg M, Labasse A, Christgau S, Cloos P, Bang Henriksen D, Chapelle JP, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005; 13: 25865.
  • 7
    Golightly YM, Marshall SW, Kraus VB, Renner JB, Villaveces A, Casteel C, et al. Serum cartilage oligomeric matrix protein, hyaluronan, high-sensitivity C-reactive protein, and keratan sulfate as predictors of incident radiographic knee osteoarthritis: differences by chronic knee symptoms [abstract]. Osteoarthritis Cartilage 2010; 18 Suppl 2: 623.
  • 8
    Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al, the OARSI FDA Osteoarthritis Biomarkers Working Group. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011; 19: 51542.
  • 9
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 103949.
  • 10
    Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494502.
  • 11
    Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 1993; 3: 32732.
  • 12
    Ruiz-Romero C, Blanco FJ. Proteomics role in the search for improved diagnosis, prognosis and treatment of osteoarthritis. Osteoarthritis Cartilage 2010; 18: 5009.
  • 13
    Nemirovskiy OV, Dufield DR, Sunyer T, Aggarwal P, Welsch DJ, Mathews WR. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Anal Biochem 2007; 361: 93101.
  • 14
    Sinz A, Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002; 23: 344556.
  • 15
    Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007; 9: R36.
  • 16
    Kamphorst JJ, van der Heijden R, DeGroot J, Lafeber FP, Reijmers TH, van El B, et al. Profiling of endogenous peptides in human synovial fluid by NanoLC-MS: method validation and peptide identification. J Proteome Res 2007; 6: 438896.
  • 17
    Albig AR, Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006; 66: 26219.
  • 18
    Ehlermann J, Weber S, Pfisterer P, Schorle H. Cloning, expression and characterization of the murine Efemp1, a gene mutated in Doyne-Honeycomb retinal dystrophy. Gene Expr Patterns 2003; 3: 4417.
  • 19
    Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1): implications for macular degenerations. J Biol Chem 2004; 279: 3046973.
  • 20
    Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of Timp3−/− mice. Arthritis Rheum 2007; 56: 9059.
  • 21
    Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004; 50: 13141.
  • 22
    Wakabayashi T, Matsumine A, Nakazora S, Hasegawa M, Iino T, Ota H, et al. Fibulin-3 negatively regulates chondrocyte differentiation. Biochem Biophys Res Commun 2010; 391: 111621.
  • 23
    Vincourt JB, Lionneton F, Kratassiouk G, Guillemin F, Netter P, Mainard D, et al. Establishment of a reliable method for direct proteome characterization of human articular cartilage. Mol Cell Proteomics 2006; 5: 198495.
  • 24
    Wu J, Liu W, Bemis A, Wang E, Qiu Y, Morris EA, et al. Comparative proteomic characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. Arthritis Rheum 2007; 56: 367584.
  • 25
    Blackburn J, Tarttelin EE, Gregory-Evans CY, Moosajee M, Gregory-Evans K. Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci 2003; 44: 461321.
  • 26
    Zweig MH, Broste SK, Reinhart RA. ROC curve analysis: an example showing the relationships among serum lipid and apolipoprotein concentrations in identifying patients with coronary artery disease. Clin Chem 1992; 38: 14258.
  • 27
    Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, et al. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther 2011; 13: R52.
  • 28
    Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006; 14: 7237.